JJP Biologics sp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2016-03-23
Share capital
3,198,900.00 PLN
Activity description

JJP Biologics is a Polish biotechnology company developing biological therapeutics supported by established companion diagnostics and a personalized-medicine strategy. Its pipeline includes JJP-1212, a potential CD89 antagonist for autoinflammatory diseases, and JJP-1008, a potential HVEM checkpoint inhibitor for solid tumors; the company seeks academic collaborators, investors, and biotechnology partners.

Registered address
ul. Bobrowiecka 6, 00-728 Warszawa, Poland
Phone
Social media
Electronic delivery address
AE:PL-80487-77162-HTUID-28

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0
Grants$3,065,430

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 198 days for 2020).

  • 202503/07/2026
  • 202402/06/2025
  • 202327/02/2024
  • 202228/06/2023
  • 202102/09/2022
  • 202001/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 8.2%
Top 4.3%
City · Warszawa6,199 / 56,772
Top 11%
Voivodeship · Mazowieckie8,810 / 76,953
Top 11%
Country · Poland33,269 / 297,266
Top 11%

Results vs industry

Revenue
This companyUSD 5.00mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -13.58mMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 17.71mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 17.76mMedianUSD 281.58kAverageUSD 8.35m

Offer

  • Biological testing
  • Biologics development
  • Biologic medicines
  • Preclinical testing
  • Clinical trials

Websites

The site is available in: Polish and English. The site targets these markets: United Kingdom.

Job offers

The company has its own careers page: jjpbiologics.com/jobs.

Authorized Representatives

Paweł Aleksander Szczepański age 45 – President of the Management Board
Louis Boon – Management Board Member
Dariusz Krzysztof Piątek age 45 – Management Board Member
Grzegorz Roman Kotowski age 58 – Management Board Member

Manner of representation

The making of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy.

Supervisory board

Abraham Bout – Supervisory Board Member
Marek Krzysztof Cybulski age 50 – Supervisory Board Member
Joerg Windisch – Supervisory Board Member
Konstantin Matentzoglu – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
57,580$777,687.7489.9997%
6,398$86,169.649.9722%
Others
18$243.110.0281%

Beneficial owners

Person

Subsidiaries

NameStake
Jjpb1008 sp. z o.o.
99%
Jjpb1212 sp. z o.o.
99%
Jjpbonko sp. z o.o.
99%

Bank accounts

Registered as a VAT taxpayer on 2016-05-25.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 50,375

MSiG notices

Publication dateEvent
Feb 5, 2024Call to creditors
Nov 18, 2020Call to creditors

Public aid

13 public aid cases recorded, with a total value of $22,776,051.

PurposeGross amount
Aid for research and development projects: experimental development
$4.4M
Aid for research and development projects: industrial research
$4.2M
De minimis aid (in accordance with Commission Regulation 2023/2831)
$18,834

European Funds

ProjectEU co-financing
Development of an innovative molecule for the immunotherapy of lung adenocarcinoma that induces targeted lysosomal degradation
$8.4M

Competitors

Name
KCR S.A.
Lipid Systems sp. z o.o.
Aronpharma sp. z o.o.
Captor Therapeutics S.A.
Molecure S.A.
Scope Fluidics S.A.
Pikralida sp. z o.o.
Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o.
Nanogroup S.A.
Bioresearch Group sp. z o.o.

Change history

DateEvent
2025-12-05Share capital increase
2025-05-19Switch to PKD 2025
2024-07-03Share capital reduction
2022-12-01Address change
2022-05-01Share capital increase

FAQ

Last updated: 2026-07-20